36. Epidermolysis bullosa Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 163 Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125

Drugs and their primary sponsors and trial info
3400930060797   
   CHU NICE
      2020   Phase 2   EUCTR2020-001542-19-FR   France;
ABH001   
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
      2012   Phase 3   NCT01749306   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
AC-203   
   TWi Biotechnology, Inc.
      2018   Phase 2   NCT03468322   Taiwan;
AGLE 102   
   Aegle Therapeutics
      2022   Phase 1/Phase 2   NCT04173650   -
ALLANTOINA   
   SCIODERM, INC
      -   Phase 3   EUCTR2014-005679-96-IT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
ALLO-ASC-DFU   
   Anterogen Co., Ltd.
      2017   -   NCT03183934   Korea, Republic of;
AVCN583601 ( Cannabidiol cream)   
   Elena Pope
      2020   Phase 2/Phase 3   NCT04613102   Canada;
Alemtuzumab   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
Allo-APZ2-EB   
   RHEACELL GmbH & Co. KG
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-FR   Austria;France;Germany;United Kingdom;United States;
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-DE   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 1/Phase 2   NCT03529877   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 1   EUCTR2018-001009-98-IT   Austria;France;Germany;Italy;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-GB   Austria;France;Germany;Italy;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-AT   Austria;France;Germany;Italy;United Kingdom;United States;
Allogeneic adipose tissue-derived MSC   
   Masarykova univerzita
      -   Phase 1;Phase 2   EUCTR2020-002936-55-CZ   Czech Republic;
Allogeneic mesenchymal stromal cells   
   King's College London
      2015   Phase 1;Phase 2   EUCTR2014-004500-30-GB   United Kingdom;
Allogeneic skin-derived ABCB5-positive mesenchymal stem cells   
   RHEACELL GmbH & Co. KG
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-FR   Austria;France;Germany;United Kingdom;United States;
      2019   Phase 1;Phase 2   EUCTR2018-001009-98-DE   Austria;France;Germany;Italy;United Kingdom;United States;
      2019   Phase 1   EUCTR2018-001009-98-IT   Austria;France;Germany;Italy;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-GB   Austria;France;Germany;Italy;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2018-001009-98-AT   Austria;France;Germany;Italy;United Kingdom;United States;
Allogenic mesenchymal stromal cells   
   King's College London
      2012   Phase 1;Phase 2   EUCTR2012-001394-87-GB   United Kingdom;
Alwextin cream   
   Northwestern University
      2009   Phase 2   NCT00825565   United States;
Anti-thymocyte globulin   
   Masonic Cancer Center, University of Minnesota
      2010   Phase 2   NCT01033552   United States;
BIOOPA dressing   
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland;
Blood test   
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT03730584   France;
Bone marrow infusion   
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
Bone marrow or umbilical cord blood (UCG) stem cell transplantation   
   Masonic Cancer Center, University of Minnesota
      2010   Phase 2   NCT01033552   United States;
Botulinic toxin   
   University Hospital, Toulouse
      2018   Phase 2/Phase 3   NCT03453632   France;
Busilvex   
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands;
Busulfan   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
      2007   -   NCT00478244   United States;
CCP-020   
   Castle Creek Pharmaceuticals, LLC
      2018   Phase 1   EUCTR2018-000439-29-GB   France;Germany;Netherlands;United Kingdom;United States;
      -   Phase 1   EUCTR2018-000439-29-NL   France;Germany;Netherlands;United Kingdom;United States;
COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin   
   Institut National de la Santé Et de la Recherche Médicale, France
      2020   Phase 1/Phase 2   NCT04186650   France;
CX501   
   CELLERIX, S.A.
      2006   -   EUCTR2005-002329-30-ES   Spain;
   Tigenix S.A.U.
      2006   Phase 2   NCT00987142   Spain;
Cannabinol (CBN)   
   InMed Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-000214-42-ES   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
      2021   Phase 2   EUCTR2021-000214-42-GR   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      2021   Phase 2   EUCTR2021-000214-42-AT   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      -   Phase 2   EUCTR2021-000214-42-FR   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      -   Phase 2   EUCTR2021-000214-42-DE   Austria;France;Germany;Greece;Israel;Italy;Serbia;
Cell transplantation   
   Royan Institute
      2010   Phase 1   NCT01908088   Iran, Islamic Republic of;
Cultured allogeneic fibroblasts   
   Intercytex Ltd
      2011   Phase 2   EUCTR2010-023121-38-GB   United Kingdom;
Cyclophosphamide   
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
      2010   Phase 2   NCT01033552   United States;
      2007   -   NCT00478244   United States;
Cyclosporine A   
   Masonic Cancer Center, University of Minnesota
      2010   Phase 2   NCT01033552   United States;
Células madre mesenquimales haploidénticas derivadas de médula ósea   
   Fundación para la Investigación Biomédica Hospital Universitario La Paz
      2017   Phase 1   EUCTR2017-000606-37-ES   Spain;
Diacerein Ointment   
   Castle Creek Pharmaceuticals, LLC
      2018   Phase 1   NCT03472287   France;Netherlands;United Kingdom;United States;
Diacerein ointment   
   Castle Creek Pharmaceuticals, LLC
      2017   Phase 2   NCT03389308   United States;
      2017   Phase 2   NCT03154333   Australia;Austria;France;Germany;Israel;Netherlands;United Kingdom;United States;
Diacerin cream   
   Tel-Aviv Sourasky Medical Center
      2015   Phase 2   NCT02470689   -
Donor mesenchymal stem cell infusions   
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
Dysport   
   Sophiahemmet
      2009   -   EUCTR2009-010763-17-SE   Sweden;
Dysport® (Botulinumtoxin A (Btx A))   
   Uppsala University
      2009   Phase 2   NCT00936533   Sweden;
EB-101   
   Abeona Therapeutics, Inc
      2020   Phase 3   NCT04227106   United States;
   Jean Yuh Tang
      2018   Phase 3   NCT03632265   -
Episalvan gel   
   Amryt Research Limited
      2018   Phase 3   EUCTR2016-002066-32-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-BE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-IT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002066-32-IE   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-ES   Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002066-32-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-002066-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-002066-32-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Erythrocine oral   
   CHU de NICE
      -   Phase 2   EUCTR2010-024428-10-FR   France;
Erythromycine   
   CHU de NICE
      -   Phase 2   EUCTR2010-024428-10-FR   France;
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA.   
   HOLOSTEM TERAPIE AVANZATE S.R.L.
      2021   Phase 2;Phase 3   EUCTR2018-000261-36-IT   France;Germany;Italy;
FCX-007 (dabocemagene autoficel   
   Castle Creek Biosciences, LLC.
      2020   Phase 3   NCT04213261   United States;
Fludarabine   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
      2010   Phase 2   NCT01033552   United States;
Fludarabine phosphate   
   Masonic Cancer Center, University of Minnesota
      2007   -   NCT00478244   United States;
Gene-modified autologous fibroblasts   
   King's College London
      2015   Phase 1   NCT02493816   United Kingdom;
Genetically corrected cultured epidermal autograft (ATMP)   
   Holostem Terapie Avanzate s.r.l.
      2017   Phase 1/Phase 2   NCT02984085   Austria;
Gentamicin   
   University of Southern California
      2018   Phase 1/Phase 2   NCT03392909   United States;
      2016   Phase 1/Phase 2   NCT02698735   -
Gentamicin Sulfate   
   Oslo University Hospital
      2020   Phase 1/Phase 2   NCT04644627   Norway;
   University of Southern California
      2018   Phase 1/Phase 2   NCT03526159   United States;
      2017   Phase 1/Phase 2   NCT03012191   United States;
Gentamicin Sulfate, Injectable   
   University of Southern California
      2019   Phase 1/Phase 2   NCT04140786   United States;
Gentamicin sulfate ointment   
   Oslo University Hospital
      2020   Phase 2   EUCTR2020-002337-15-NO   Norway;
Granulocyte Colony Stimulating Factor (GCSF)   
   Vanderbilt University Medical Center
      2012   Phase 2   NCT01538862   United States;
HOLOGENE17   
   Holostem Terapie Avanzate s.r.l.
      2017   Phase 1;Phase 2   EUCTR2016-000095-17-AT   Austria;
HOLOGENE7   
   Holostem Terapie Avanzate s.r.l.
      2016   Phase 1;Phase 2   EUCTR2015-004592-74-AT   Austria;
HP802-247   
   Healthpoint
      2012   Phase 2   NCT01528306   United States;
Hematopoietic bone marrow transplantation   
   Masonic Cancer Center, University of Minnesota
      2007   -   NCT00478244   United States;
Hologene 5 DS   
   HOLOSTEM TERAPIE AVANZATE S.R.L.
      2021   Phase 2;Phase 3   EUCTR2018-000261-36-IT   France;Germany;Italy;
Human Allogeneic WJ-MSCs   
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland;
Human Umbilical Cord Blood-derived Mesenchymal Stem Cells   
   Gangnam Severance Hospital
      2016   Phase 1/Phase 2   NCT04520022   Korea, Republic of;
Human allogeneic adipose tissue-derived mesenchymal stem cells expanded   
   Masarykova univerzita
      -   Phase 1;Phase 2   EUCTR2020-002936-55-CZ   Czech Republic;
Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh   
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
Human fibroblast-derived dermal substitute, Dermagraft   
   Shire Regenerative Medicine, Inc.
      2013   -   EUCTR2012-001815-21-PT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-ES   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-DE   Australia;Austria;Germany;Portugal;Spain;United States;
      2013   -   EUCTR2012-001815-21-AT   Austria;Canada;France;Germany;Poland;Portugal;Spain;United States;
ICX-RHY-013   
   Intercytex Ltd
      2011   Phase 2   EUCTR2010-023121-38-GB   United Kingdom;
INM-755   
   InMed Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-000214-42-ES   Austria;France;Germany;Greece;Israel;Italy;Serbia;Spain;
      2021   Phase 2   EUCTR2021-000214-42-GR   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      2021   Phase 2   EUCTR2021-000214-42-AT   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      -   Phase 2   EUCTR2021-000214-42-FR   Austria;France;Germany;Greece;Israel;Italy;Serbia;
      -   Phase 2   EUCTR2021-000214-42-DE   Austria;France;Germany;Greece;Israel;Italy;Serbia;
INM-755 (cannabinol) cream   
   InMed Pharmaceuticals Inc.
      2021   Phase 2   NCT04908215   -
Infectogenta   
   Oslo University Hospital
      2020   Phase 2   EUCTR2020-002337-15-NO   Norway;
Isotretinoin   
   University of North Carolina
      2000   Phase 1   NCT00014729   -
Ixekizumab   
   CHU NICE
      2020   Phase 2   EUCTR2020-001542-19-FR   France;
Jojoba oil with broccoli sprout extract   
   Johns Hopkins University
      2015   Phase 1   NCT02592954   United States;
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets   
   Stanford University
      2010   Phase 1/Phase 2   NCT01263379   United States;
Lorazepam   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
Losartan HEXAL   
   Medical Center - University of Freiburg
      2017   Phase 2   EUCTR2015-003670-32-AT   Austria;Germany;
      -   Phase 2   EUCTR2015-003670-32-DE   Austria;Germany;
MESENCHYMAL STEM CELLS (MSCS)   
   Fundación para la Investigación Biomédica Hospital Universitario La Paz
      2017   Phase 1   EUCTR2017-000606-37-ES   Spain;
Mesenchymal Stem Cells extracted from bone marrow   
   Fundación para la Investigación Biomédica Hospital Universitario La Paz
      2017   Phase 1   EUCTR2017-000606-37-ES   Spain;
Mesenchymal Stromal Cells   
   Ishin Pharmaceutical Co. Ltd.
      2017   Phase 1,2   JPRN-UMIN000028366   Japan;
Mesenchymal stem cell transplantation   
   Masonic Cancer Center, University of Minnesota
      2010   Phase 2   NCT01033552   United States;
Mesenchymal stem cells derived from bone marrow (BM-MSCs)   
   Instituto de Investigación Hospital Universitario La Paz
      2018   Phase 1/Phase 2   NCT04153630   Spain;
Methoxsalen   
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004359   -
Morphine sulphate in intrasite gel   
   Institute of Child Health
      2005   Phase 4   NCT00231517   United Kingdom;
Mycophenolate mofetil   
   Masonic Cancer Center, University of Minnesota
      2010   Phase 2   NCT01033552   United States;
Normal saline   
   Phoenix Tissue Repair, Inc.
      2019   Phase 1/Phase 2   NCT03752905   United States;
Occlusive non adherent dressing   
   Tigenix S.A.U.
      2006   Phase 2   NCT00987142   Spain;
Oleogel-S10   
   Amryt Research Limited
      2018   Phase 3   EUCTR2016-002066-32-HU   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Singapore;Spain;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-HR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Mexico;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2018   Phase 3   EUCTR2016-002066-32-BE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2017   Phase 3   NCT03068780   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002066-32-IT   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002066-32-IE   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-GR   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
      2017   Phase 3   EUCTR2016-002066-32-ES   Australia;Austria;Croatia;France;Germany;Greece;Ireland;Israel;Italy;Mexico;Spain;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002066-32-AT   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-002066-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-002066-32-CZ   Argentina;Australia;Austria;Belgium;Brazil;Chile;Colombia;Croatia;Czech Republic;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Romania;Russian Federation;Serbia;Singapore;Spain;Switzerland;Ukraine;United Kingdom;United States;
Open Label Topical Beremagene Geperpavec (B-VEC)   
   Krystal Biotech, Inc.
      2021   Phase 3   NCT04917874   United States;
Oral erythromycin   
   Centre Hospitalier Universitaire de Nice
      2011   Phase 3   NCT01340235   France;
POLYPHENON E   
   CHU de NICE
      2010   -   EUCTR2009-012750-21-FR   France;
PTR-01   
   Phoenix Tissue Repair, Inc.
      2020   Phase 2   NCT04599881   United States;
      2019   Phase 1/Phase 2   NCT03752905   United States;
Palifermin   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
Polyphenon E   
   Centre Hospitalier Universitaire de Nice
      2010   Phase 2   NCT00951964   France;
Pregabalin   
   The Hospital for Sick Children
      2019   Phase 3   NCT03928093   Canada;
Psorcutan-Ointment   
   Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
      2016   Phase 2   EUCTR2016-001967-35-AT   Austria;
QR-313   
   Phoenicis Therapeutics
      2018   Phase 1/Phase 2   NCT03605069   France;Spain;United States;
QR-313 Gel for Topical (Cutaneous) Administration   
   ProQR Therapeutics
      -   Phase 1;Phase 2   EUCTR2017-004806-17-FR   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
   ProQR Theraputics
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-ES   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
   Wings Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-GB   Czech Republic;France;Germany;Spain;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-DE   Czech Republic;France;Germany;Spain;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2017-004806-17-CZ   Czech Republic;France;Germany;Spain;United Kingdom;United States;
REGE pro dressing   
   Egyptian Atomic Energy Authority
      2017   -   NCT03942250   Egypt;
RGN-137   
   Lenus Therapeutics, LLC
      2019   Phase 2   NCT03578029   United States;
Rigosertib   
   Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria
      2017   Phase 2   EUCTR2016-003832-19-AT   Austria;
Rigosertib Oral Capsules / Rigosertib Intravenous   
   Prof. Johann Bauer
      2021   Phase 1/Phase 2   NCT03786237   Austria;
Rigosertib Sodium   
   Thomas Jefferson University
      2021   Early Phase 1   NCT04177498   United States;
Rituximab   
   Research group of rare intractable dermatologial disorder
      2010   Phase 2   JPRN-UMIN000004428   Japan;
Ropivacaine   
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT03730584   France;
SASS   
   CHU de Quebec-Universite Laval
      2019   Early Phase 1   NCT04171661   Canada;
SD-101   
   Scioderm INC, An Amicus Therapeutics Company
      -   Phase 3   EUCTR2014-002288-14-BE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, An Amicus Therapeutics Company
      2016   Phase 3   EUCTR2014-002288-14-LT   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002288-14-PL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002288-14-DE   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-NL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-GB   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, INC
      2016   Phase 3   EUCTR2014-005679-96-ES   Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-GB   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   -   EUCTR2014-005679-96-NL   Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Scioderm, INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-005679-96-LT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-DE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2014-005679-96-PL   Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, INC.
      2016   Phase 3   EUCTR2014-002288-14-ES   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-IT   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
SD-101 Dermal Cream ()   
   Scioderm, Inc.
      2014   Phase 2   NCT02014376   United States;
SD-101 dermal cream ()   
   Scioderm, Inc.
      2014   Phase 2   NCT02090283   United States;
      2014   Phase 2   NCT02014376   United States;
SD-101-6.0 cream   
   Scioderm, Inc.
      2015   Phase 3   NCT02670330   Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   NCT02384460   Australia;Austria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Serbia;Spain;United Kingdom;United States;
SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1   
   King's College London
      2016   Phase 1   EUCTR2014-004884-19-GB   United Kingdom;
SIN RV-mediated COL7A1 corrected autologous skin equivalent   
   INSERM
      2019   Phase 1;Phase 2   EUCTR2016-002790-35-FR   France;
See below for FCX-007 description)   
   Castle Creek Biosciences, LLC.
      2020   Phase 3   NCT04213261   United States;
Sericare   
   Birken GmbH
      2010   -   EUCTR2010-019945-24-DE   Germany;
Sericare®   
   Birken AG
      2010   Phase 2   NCT01294241   Germany;
Serlopitant Tablet   
   Stanford University
      2019   Phase 2   NCT03836001   United States;
SimpleCare   
   EB House Austria
      2013   Phase 3   EUCTR2013-002034-21-AT   Austria;
Sirolimus   
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia;
Sirolimus,   
   Stanford University
      2016   Phase 2   NCT02960997   United States;
TC-MSC   
   King's College London
      2015   Phase 1;Phase 2   EUCTR2014-004500-30-GB   United Kingdom;
      2012   Phase 1;Phase 2   EUCTR2012-001394-87-GB   United Kingdom;
   Universitair Medisch Centrum Utrecht
      2014   Phase 2   EUCTR2012-000605-72-NL   Netherlands;
Tacrolimus   
   Columbia University
      2009   Early Phase 1   NCT00881556   United States;
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
Taltz   
   CHU NICE
      2020   Phase 2   EUCTR2020-001542-19-FR   France;
Tetracyclin   
   Rambam Health Care Campus
      2006   Phase 4   NCT00336154   Israel;
Thymoglobulin   
   Masonic Cancer Center, University of Minnesota
      2016   Phase 2   NCT02582775   United States;
TolaSure Topical Gel   
   BioMendics, LLC
      2021   Phase 1   NCT05062070   United States;
Topical BPM31510 Cream   
   Shasa Hu
      2016   Phase 1   NCT02793960   United States;
Topical Beremagene Geperpavec   
   Krystal Biotech, Inc.
      2020   Phase 3   NCT04491604   United States;
Topical beremagene geperpavec   
   Krystal Biotech, Inc.
      2018   Phase 2   NCT03536143   United States;
Topical opiod   
   Institute of Child Health
      2005   Phase 4   NCT00231517   United Kingdom;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL17A1-encoding retroviral vector   
   Holostem Terapie Avanzate s.r.l.
      2017   Phase 1;Phase 2   EUCTR2016-000095-17-AT   Austria;
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a COL7A1-encoding retroviral vector, obtained from secondary culture of ex vivo expanded autologous human keratinocytes.   
   Holostem Terapie Avanzate s.r.l.
      2016   Phase 1;Phase 2   EUCTR2015-004592-74-AT   Austria;
Transplantation   
   Holostem Terapie Avanzate s.r.l.
      2022   Phase 2/Phase 3   NCT05111600   France;Germany;Italy;
Transvamix (100mg/mL THC, 50mg/mL CBD)   
   University Medical Center Groningen
      -   Phase 2   EUCTR2021-000103-20-NL   Netherlands;
Trimethoprim   
   The Hospital for Sick Children
      2006   Phase 2   NCT00380640   Canada;
Triterpene dry extract from birch cork   
   Birken GmbH
      2010   -   EUCTR2010-019945-24-DE   Germany;
Unavailable   
   ProQR Therapeutics
      -   Phase 1;Phase 2   EUCTR2017-004806-17-FR   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
   ProQR Theraputics
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-ES   Austria;Canada;Czech Republic;France;Germany;Spain;United Kingdom;United States;
   Wings Therapeutics Inc.
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-GB   Czech Republic;France;Germany;Spain;United Kingdom;United States;
      2018   Phase 1;Phase 2   EUCTR2017-004806-17-DE   Czech Republic;France;Germany;Spain;United Kingdom;United States;
      -   Phase 1;Phase 2   EUCTR2017-004806-17-CZ   Czech Republic;France;Germany;Spain;United Kingdom;United States;
VPD-737   
   Jean Yuh Tang
      2016   Phase 2   NCT02654483   United States;
Vehicle   
   Premier Specialists, Australia
      2016   Phase 2   NCT03016715   Australia;
   Stanford University
      2016   Phase 2   NCT02960997   United States;
   TWi Biotechnology, Inc.
      2018   Phase 2   NCT03468322   Taiwan;
Vehicle (SD-101 )   
   Scioderm, Inc.
      2014   Phase 2   NCT02014376   United States;
Vehicle Cream   
   InMed Pharmaceuticals Inc.
      2021   Phase 2   NCT04908215   -
Vehicle Topical Gel   
   BioMendics, LLC
      2021   Phase 1   NCT05062070   United States;
WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS   
   Medical University of Warsaw
      2020   Phase 1;Phase 2   EUCTR2018-003890-91-PL   Poland;
Zorblisa   
   Scioderm INC, An Amicus Therapeutics Company
      -   Phase 3   EUCTR2014-002288-14-BE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, An Amicus Therapeutics Company
      2016   Phase 3   EUCTR2014-002288-14-LT   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002288-14-PL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002288-14-DE   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-NL   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-GB   Australia;Austria;Belgium;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, INC
      2016   Phase 3   EUCTR2014-005679-96-ES   Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-GB   Australia;Austria;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-AT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   -   EUCTR2014-005679-96-NL   Australia;Austria;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Scioderm, INC, An Amicus Therapeutics Company
      2017   Phase 3   EUCTR2014-005679-96-LT   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-005679-96-DE   Australia;Austria;Belgium;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2014-005679-96-PL   Australia;Austria;Bulgaria;France;Germany;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States;
   Scioderm, INC.
      2016   Phase 3   EUCTR2014-002288-14-ES   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002288-14-IT   Austria;Belgium;France;Germany;Italy;Lithuania;Netherlands;Poland;Spain;United Kingdom;United States;